PE20020769A1 - Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos - Google Patents

Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos

Info

Publication number
PE20020769A1
PE20020769A1 PE2001000553A PE2001000553A PE20020769A1 PE 20020769 A1 PE20020769 A1 PE 20020769A1 PE 2001000553 A PE2001000553 A PE 2001000553A PE 2001000553 A PE2001000553 A PE 2001000553A PE 20020769 A1 PE20020769 A1 PE 20020769A1
Authority
PE
Peru
Prior art keywords
tegafur
combination
day
oxaliplatin
uracil
Prior art date
Application number
PE2001000553A
Other languages
English (en)
Inventor
Michel Chazard
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20020769A1 publication Critical patent/PE20020769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE LA COMBINACION DE: a)TEGAFUR (1-(2-TETRAHIDROFURIL)-5-FLUOROURACILO, UTILIZANDO DE 1mg/Kg/DIA A 30 mg/Kg/DIA; b)URACILO, UTILIZANDO DE 1mg/Kg/DIA A 50mg/Kg/DIA Y c)ACIDO FOLINICO O FOLINATO DE CALCIO UTILIZANDO 90mg/DIA PUEDE POTENCIAR EL EFECTO DEL OXALIPLATINO UTILIZANDO DE 50 mg/m2/DIA; SIENDO LA RELACION MOLAR DE TEGAFUR Y URACILO DE 1:4. LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DEL CANCER COLORECTAL
PE2001000553A 2000-03-08 2001-06-12 Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos PE20020769A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18784200P 2000-03-08 2000-03-08
US23114700P 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
PE20020769A1 true PE20020769A1 (es) 2002-09-06

Family

ID=26883457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000553A PE20020769A1 (es) 2000-03-08 2001-06-12 Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos

Country Status (5)

Country Link
US (1) US6602870B2 (es)
AR (1) AR027624A1 (es)
AU (1) AU2001240001A1 (es)
PE (1) PE20020769A1 (es)
WO (1) WO2001066102A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
FR2834641B1 (fr) * 2002-01-14 2005-04-22 Ct Regional De Lutte Contre Le Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
EP1604991B1 (en) * 2003-03-14 2008-09-17 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator and antitumor agent
KR100844477B1 (ko) * 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
SI1757283T1 (sl) * 2004-06-09 2013-01-31 Taiho Pharmaceutical Co., Ltd. Ojačevalec protitumorskega učinka, protitumorsko sredstvo in postopek terapije za rak
US20080081301A1 (en) * 2006-10-03 2008-04-03 Hannum Mark C Low NOx combustion
ATE530188T1 (de) * 2007-03-02 2011-11-15 Univ Wollongong Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
US8007470B2 (en) * 2007-07-10 2011-08-30 Cook Medical Technologies Llc Minimally invasive medical device and method for delivery of therapeutic or diagnostic agents into a vessel wall
AU2008356312B2 (en) * 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition

Also Published As

Publication number Publication date
US6602870B2 (en) 2003-08-05
WO2001066102A3 (en) 2001-12-20
WO2001066102A2 (en) 2001-09-13
AU2001240001A1 (en) 2001-09-17
US20020045632A1 (en) 2002-04-18
AR027624A1 (es) 2003-04-02

Similar Documents

Publication Publication Date Title
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
DE50110049D1 (de) Magnesium-ammonium-phosphat-zemente, deren herstellung und verwendung
EA200300834A1 (ru) Антагонисты фактора, высвобождающего кортикотропин
CY1113103T1 (el) Φωσφονικα νουκλεοσιδιων και αναλογα εξ αυτων για την αγωγη των λοιμωξεων-hpv
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BR0315959A (pt) Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
CY1107506T1 (el) Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης
AP2001002204A0 (en) Pyrazole derivatives.
GB0124933D0 (en) Chemical compounds
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
PE20020769A1 (es) Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos
CY1107542T1 (el) Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
BR0109542A (pt) Derivados de imidazopirina alquilados
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
NO20030772L (no) Fremgangsmate til fremstilling av vannfritt azitromycin
ATE394403T1 (de) Anti-angiogenetische arzneimittel
DE60112960D1 (de) Kondensierte pyridoindolderivate
NO20021048L (no) Chalkonkumariner
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
ATE259813T1 (de) Triazolopyrimidinderivate
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal